Metabolic engineering Escherichia coli for efficient production of icariside D2

Abstract Background Icariside D2 is a plant-derived natural glycoside with pharmacological activities of inhibiting angiotensin-converting enzyme and killing leukemia cancer cells. Production of icariside D2 by plant extraction and chemical synthesis is inefficient and environmentally unfriendly. Mi...

Full description

Bibliographic Details
Main Authors: Xue Liu, Lingling Li, Jincong Liu, Jianjun Qiao, Guang-Rong Zhao
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Biotechnology for Biofuels
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13068-019-1601-x
_version_ 1818230309098881024
author Xue Liu
Lingling Li
Jincong Liu
Jianjun Qiao
Guang-Rong Zhao
author_facet Xue Liu
Lingling Li
Jincong Liu
Jianjun Qiao
Guang-Rong Zhao
author_sort Xue Liu
collection DOAJ
description Abstract Background Icariside D2 is a plant-derived natural glycoside with pharmacological activities of inhibiting angiotensin-converting enzyme and killing leukemia cancer cells. Production of icariside D2 by plant extraction and chemical synthesis is inefficient and environmentally unfriendly. Microbial cell factory offers an attractive route for economical production of icariside D2 from renewable and sustainable bioresources. Results We metabolically constructed the biosynthetic pathway of icariside D2 in engineered Escherichia coli. We screened the uridine diphosphate glycosyltransferases (UGTs) and obtained an active RrUGT3 that regio-specifically glycosylated tyrosol at phenolic position to exclusively synthesize icariside D2. We put heterologous genes in E. coli cell for the de novo biosynthesis of icariside D2. By fine-tuning promoter and copy number as well as balancing gene expression pattern to decrease metabolic burden, the BMD10 monoculture was constructed. Parallelly, for balancing pathway strength, we established the BMT23–BMD12 coculture by distributing the icariside D2 biosynthetic genes to two E. coli strains BMT23 and BMD12, responsible for biosynthesis of tyrosol from preferential xylose and icariside D2 from glucose, respectively. Under the optimal conditions in fed-batch shake-flask fermentation, the BMD10 monoculture produced 3.80 g/L of icariside D2 using glucose as sole carbon source, and the BMT23–BMD12 coculture produced 2.92 g/L of icariside D2 using glucose–xylose mixture. Conclusions We for the first time reported the engineered E. coli for the de novo efficient production of icariside D2 with gram titer. It would be potent and sustainable approach for microbial production of icariside D2 from renewable carbon sources. E. coli–E. coli coculture approach is not limited to glycoside production, but could also be applied to other bioproducts.
first_indexed 2024-12-12T10:32:27Z
format Article
id doaj.art-31292ff27aa9420889f4e0ec42a41112
institution Directory Open Access Journal
issn 1754-6834
language English
last_indexed 2024-12-12T10:32:27Z
publishDate 2019-11-01
publisher BMC
record_format Article
series Biotechnology for Biofuels
spelling doaj.art-31292ff27aa9420889f4e0ec42a411122022-12-22T00:27:19ZengBMCBiotechnology for Biofuels1754-68342019-11-0112111210.1186/s13068-019-1601-xMetabolic engineering Escherichia coli for efficient production of icariside D2Xue Liu0Lingling Li1Jincong Liu2Jianjun Qiao3Guang-Rong Zhao4Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin UniversityFrontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin UniversityFrontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin UniversityFrontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin UniversityFrontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin UniversityAbstract Background Icariside D2 is a plant-derived natural glycoside with pharmacological activities of inhibiting angiotensin-converting enzyme and killing leukemia cancer cells. Production of icariside D2 by plant extraction and chemical synthesis is inefficient and environmentally unfriendly. Microbial cell factory offers an attractive route for economical production of icariside D2 from renewable and sustainable bioresources. Results We metabolically constructed the biosynthetic pathway of icariside D2 in engineered Escherichia coli. We screened the uridine diphosphate glycosyltransferases (UGTs) and obtained an active RrUGT3 that regio-specifically glycosylated tyrosol at phenolic position to exclusively synthesize icariside D2. We put heterologous genes in E. coli cell for the de novo biosynthesis of icariside D2. By fine-tuning promoter and copy number as well as balancing gene expression pattern to decrease metabolic burden, the BMD10 monoculture was constructed. Parallelly, for balancing pathway strength, we established the BMT23–BMD12 coculture by distributing the icariside D2 biosynthetic genes to two E. coli strains BMT23 and BMD12, responsible for biosynthesis of tyrosol from preferential xylose and icariside D2 from glucose, respectively. Under the optimal conditions in fed-batch shake-flask fermentation, the BMD10 monoculture produced 3.80 g/L of icariside D2 using glucose as sole carbon source, and the BMT23–BMD12 coculture produced 2.92 g/L of icariside D2 using glucose–xylose mixture. Conclusions We for the first time reported the engineered E. coli for the de novo efficient production of icariside D2 with gram titer. It would be potent and sustainable approach for microbial production of icariside D2 from renewable carbon sources. E. coli–E. coli coculture approach is not limited to glycoside production, but could also be applied to other bioproducts.http://link.springer.com/article/10.1186/s13068-019-1601-xIcariside D2Escherichia coliCocultureSynthetic biologyMetabolic engineering
spellingShingle Xue Liu
Lingling Li
Jincong Liu
Jianjun Qiao
Guang-Rong Zhao
Metabolic engineering Escherichia coli for efficient production of icariside D2
Biotechnology for Biofuels
Icariside D2
Escherichia coli
Coculture
Synthetic biology
Metabolic engineering
title Metabolic engineering Escherichia coli for efficient production of icariside D2
title_full Metabolic engineering Escherichia coli for efficient production of icariside D2
title_fullStr Metabolic engineering Escherichia coli for efficient production of icariside D2
title_full_unstemmed Metabolic engineering Escherichia coli for efficient production of icariside D2
title_short Metabolic engineering Escherichia coli for efficient production of icariside D2
title_sort metabolic engineering escherichia coli for efficient production of icariside d2
topic Icariside D2
Escherichia coli
Coculture
Synthetic biology
Metabolic engineering
url http://link.springer.com/article/10.1186/s13068-019-1601-x
work_keys_str_mv AT xueliu metabolicengineeringescherichiacoliforefficientproductionoficarisided2
AT linglingli metabolicengineeringescherichiacoliforefficientproductionoficarisided2
AT jincongliu metabolicengineeringescherichiacoliforefficientproductionoficarisided2
AT jianjunqiao metabolicengineeringescherichiacoliforefficientproductionoficarisided2
AT guangrongzhao metabolicengineeringescherichiacoliforefficientproductionoficarisided2